Botanix PharmaceuticalsBXPHF Gross Margin % is 63.94% as of Dec. 2025, which is 59% above its 10-year median of 40.28. The stock has 7 warning signs investors should review. Among 732 Biotechnology companies, Botanix Pharmaceuticals ranks better than 50.55% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Botanix Pharmaceuticals had a gross margin of 63.94% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Botanix Pharmaceuticals Gross Margin % Related Terms
Botanix Pharmaceuticals Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BXPHF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Botanix Pharmaceuticals's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Botanix Pharmaceuticals Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Botanix Pharmaceuticals's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Botanix Pharmaceuticals (BXPHF) has a Gross Margin % of 63.94% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Botanix Pharmaceuticals and its competitors. This is 59% above median its historical median of 40.28. Over the past decade, Botanix Pharmaceuticals' Gross Margin % has ranged from 40.28 to 61.25. According to the industry distribution chart, Botanix Pharmaceuticals ranks #362 out of 732 companies in the Biotechnology industry, placing it in the top 49.5%.
Is Botanix Pharmaceuticals' Gross Margin % too high?
Botanix Pharmaceuticals' current Gross Margin % of 63.94% is 59% above median its 10-year median of 40.28. Over the past 10 years, this metric has ranged from a low of 40.28 to a high of 61.25. The Biotechnology industry median Gross Margin % is 60.91. Botanix Pharmaceuticals' value of 63.94% is 5% above this industry median. Based on the distribution chart, Botanix Pharmaceuticals ranks #362 out of 732 companies in the Biotechnology industry, which is above the industry midpoint.
How does Botanix Pharmaceuticals' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Botanix Pharmaceuticals ranks #362 out of 732 companies for Gross Margin %. This puts Botanix Pharmaceuticals in the upper half of its industry. The industry median Gross Margin % is 60.91. Botanix Pharmaceuticals' value of 63.94% is 5% above this benchmark. Historically, Botanix Pharmaceuticals' own Gross Margin % has ranged from 40.28 to 61.25 over the past decade. While the company's 10-year median is 40.28 vs. the industry median of 60.91, Botanix Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Botanix Pharmaceuticals's current Gross Margin % of 63.94% is 5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Botanix Pharmaceuticals and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Botanix Pharmaceuticals's current Gross Margin % is 63.94%, which is 59% above median its own 10-year median of 40.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Botanix Pharmaceuticals stock overvalued right now?
Botanix Pharmaceuticals (BXPHF) has a current Gross Margin % of 63.94%. The current Gross Margin % is 63.94%, which is 59% above median its 10-year median of 40.28 and 5% above the Biotechnology industry median of 60.91. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Botanix Pharmaceuticals (BXPHF), the current Gross Margin % is 63.94% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXPHF has been successfully added to your 